Product Description

Sotolacib, an acrylamide-derived KRAS inhibitor, was developed by Amgen and is currently in clinical trials for the treatment of solid tumors with KRAS G12C mutations. This mutation accounts for more than 50% of all KRAS mutations. It is the first experimental KRAS inhibitor. The drug currently in development [MRTX849] has the same target.